Verseon Corporation
47071 Bayside Pkwy
Fremont
California
94538
United States
Tel: 510-225-9000
Fax: 510-225-9001
Website: https://www.verseon.com/
Email: info@verseon.com
30 articles about Verseon Corporation
-
The pharmaceutical industry is expected to spend more than $3 billion on artificial intelligence by 2025, but advocates say it is not yet living up to its potential.
-
Verseon has acquired Edammo, an artificial intelligence-focused company, to deepen its own AI-based drug discovery platform. Financial terms were not disclosed.
-
Quality by design principles, when fully optimized, can decouple much of the process from the molecule itself, leading to significant efficiencies.
-
What sets Verseon apart is its use of molecular physics modeling to enable the atomic-level engineering of new molecules. The company has 14 small molecule drugs in development.
-
Verseon Presents Two Precision Oral Anticoagulants with Low Bleeding at International Stroke Conference
2/11/2019
The new drug candidates, products of Verseon’s computationally driven drug discovery platform, could become the first anticoagulants suitable for long-term co-administration with antiplatelet drugs for patients with coronary artery disease.
-
Verseon Corporation ("Verseon" or the "Company"): Result of AGM and Changes to the Board
11/6/2018
Verseon Corporation announces that all resolutions put to shareholders were duly passed during the Annual General Meeting ("AGM") held on November 5, 2018 at 14:00 PDT.
-
Verseon Interim Report Charts Progress of Development Programs as It Submits Phase I Protocol for Precision Anticoagulant
8/14/2018
Verseon’s drug discovery program, based on an industry-leading in silico platform, progresses four programs with multiple novel compounds in anticoagulation, HAE, DME, and oncology.
-
Verseon to Initiate Phase I Study to Evaluate a New Precision Oral Anticoagulant with Reduced Bleeding Risk
6/14/2018
First-in-human phase I trial in Australia for its lead-PROAC VE-1902, which has successfully completed regulatory toxicology studies and was well-tolerated in 28-day repeat dosing.
-
Verseon Presents New Data on its Precision Oral Anticoagulants at BIO International Convention
6/11/2018
Verseon presented new preclinical data on its novel class of precision oral anticoagulants (PROACs) at last week’s BIO International Convention in Boston.
-
Verseon Presents New Efficacy Results on Oral Diabetic Macular Edema Drug Candidate at Vision and Ophthalmology Conference
5/2/2018
Verseon presented new efficacy results on its diabetic macular edema drug candidates at the Association for Research in Vision and Ophthalmology (ARVO) 2018 annual meeting in Honolulu this week.
-
The 2018 American Association for Cancer Research (AACR) is being held in Chicago. Here’s a roundup of some of today’s company news.
-
Verseon Presents Anticancer Drug Candidates Targeting Multidrug Resistant Cancers
4/18/2018
Verseon presented new preclinical studies on its anticancer drug candidates at the American Association for Cancer Research (AACR) annual meeting yesterday.
-
Verseon Presents Hereditary Angioedema Program at 2018 Biotech Showcase Conference
1/10/2018
Verseon presented preclinical results in its hereditary angioedema program at the 2018 Biotech Showcase in San Francisco yesterday, January 9.
-
Verseon Presents Second Anticoagulation Candidate for Clinical Trials at AHA 2017
11/15/2017
VE-2851 shows excellent efficacy paired with low bleeding risk in preclinical testing and is expected to enter clinical trials in 2018.
-
Verseon’s Novel Anticancer Agents for Multidrug Resistant Tumors Presented at BIO-Europe 2017
11/8/2017
The data suggest that these drug candidates may be especially well-suited for the treatment of solid tumors resistant to existing chemotherapy agents.
-
Verseon to Present Preclinical Data on Novel Anticancer Candidates for Use against Multidrug Resistant Cancers
10/31/2017
The results will be shown at the BIO-Europe conference held in Berlin from November 6–8, 2017.
-
Leading Pharmaceutical Executive Dr. Robert Karr Joins Verseon’s Board of Directors
10/24/2017
Leading pharmaceutical executive and biotech entrepreneur Dr. Robert W. Karr was recently elected as a Non-Executive Director of Verseon, a California-based pharmaceutical company.
-
Verseon Developing Oral Treatment For Hereditary Angioedema
9/26/2017
-
Verseon Reveals Preclinical Data On Novel Drug Candidates To Treat Diabetic Macular Edema
6/26/2017
-
Unique Mechanism Of Action Of Verseon’s Novel Class Of Anticoagulants To Be Presented At American Chemical Society Meeting
3/30/2017